戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e compounds can inhibit both mouse and human osteoclast activity.
2 sions in PC-3 implanted tibias by inhibiting osteoclast activity.
3 inavir (LPV) and amprenavir did not increase osteoclast activity.
4 cancer cells that are involved in increasing osteoclast activity.
5 lalanine had increased bone mass and reduced osteoclast activity.
6 rly adulthood, show increased osteoblast and osteoclast activity.
7                    Other fractions inhibited osteoclast activity.
8 amate is less important in regulating mature osteoclast activity.
9 day 7 of culture was ineffective in reducing osteoclast activity.
10 factors produced by osteoclasts that inhibit osteoclast activity.
11 used appeared to be the strongest inducer of osteoclast activity.
12 nt of osteoporosis associated with increased osteoclast activity.
13 , immune modulation, and balanced osteoblast-osteoclast activity.
14 , function and erythropoiesis independent of osteoclast activity.
15 staining around struts, suggesting potential osteoclast activity.
16 plicates bone regeneration with reduction in osteoclast activity.
17  tooth root resorption mediated by increased osteoclast activity.
18 GFbeta level is elevated and correlates with osteoclast activity.
19 to suppress inflammatory RANKL signaling and osteoclast activity.
20  bone interface exhibited microfractures and osteoclast activity.
21 n to regulate osteoblast differentiation and osteoclast activity.
22 her with subchondral bone loss and increased osteoclast activity.
23 ited bone loss and resorption by suppressing osteoclast activity.
24 neral density, consistent with inhibition of osteoclast activity.
25 mpared with WT controls due to a decrease in osteoclast activity.
26 rosine kinase also mediates RANKL-stimulated osteoclast activity.
27 ivity and bone formation, and an increase in osteoclast activity.
28 dral bone are likely attributed to increased osteoclast activity.
29 ls, indicating that Hh signaling is vital to osteoclast activity.
30 ing formation were measured as indicators of osteoclast activity.
31 duced bone mass, mainly because of increased osteoclast activity.
32  functions as an autocrine factor regulating osteoclast activity.
33 esence of necrotic bone tissue and increased osteoclast activity.
34 eoporosis reflects a relative enhancement of osteoclast activity.
35  a role for NO66 in tumor growth in bone and osteoclast activity.
36 er than RANKL may mediate the cancer-induced osteoclast activity.
37 itions, acting mainly through suppression of osteoclast activity.
38 ating that mu-calpain is required for normal osteoclast activity.
39 ncy osteolytic bone metastases, and enhanced osteoclast activity.
40 opause by the balance between osteoblast and osteoclast activity.
41 ANKL) promotes resorption through regulating osteoclast activity.
42 t LPA1 is essential for in vitro and in vivo osteoclast activities.
43 decreased calcium efflux, medium PGE(2), and osteoclast activity; Acid led to an increase in all thre
44 n, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of
45 els and patients with glioblastoma, altering osteoclast activities and increasing the number of skull
46 ha deficiency with respect to stimulation of osteoclast activity and also augments osteoblast prolife
47  increased bone mass caused by inhibition of osteoclast activity and also the strongly reduced bone f
48  osteoclast precursors, leading to increased osteoclast activity and an overall TMJ subchondral trabe
49              However, the effects of CypA on osteoclast activity and bone maintenance are entirely un
50 oth injury, Smoc2(-/-) mutants had increased osteoclast activity and bone resorption surrounding the
51 nuria, and hypoglycemia leading to increased osteoclast activity and bone resorption.
52  genes, many of which were characteristic of osteoclast activity and differentiation, in particular m
53 coupling signals coordinating osteoblast and osteoclast activity and finely tuned expression of infla
54  of skeletal disorders mediated by increased osteoclast activity and IRF8's role in osteoclastogenesi
55                      The kinase Src promotes osteoclast activity and is activated in osteoclasts by t
56                                  It inhibits osteoclast activity and is thought to result in a net in
57            DUSP-1 is a critical regulator of osteoclast activity and limits bone destruction in an ex
58  roles for ASC as an antioxidant suppressing osteoclast activity and number as well as a cofactor pro
59                       Zol markedly inhibited osteoclast activity and recruitment, promoting osteogeni
60 us delivery of these miRNAs in vivo inhibits osteoclast activity and reduces osteolytic bone metastas
61 that calpain activity is required for normal osteoclast activity and suggest that calcitonin inhibits
62 idate to inhibit multiple myeloma growth and osteoclast activity and that it should receive attention
63  indirectly on dentinogenesis by controlling osteoclast activity and the signaling network related to
64 osphatase type 5b, but ankle loading reduced osteoclast activity and those levels (all P < 0.05).
65 of the galectins family, exhibit accelerated osteoclasts activity and bone turnover, which culminates
66 y plays a critical role in the regulation of osteoclast activity, and activation of the pathway is de
67 ng diminished osteoblast activity, increased osteoclast activity, and altered phosphate homeostasis b
68 ression, a reduction in RANKL expression and osteoclast activity, and an increase in alveolar bone fo
69 KL and TNF-alpha promote osteoclastogenesis, osteoclast activity, and bone loss, WP9QY prevented the
70 ntly reduced inflammatory cell infiltration, osteoclast activity, and bone loss.
71           This agent acts as an inhibitor of osteoclast activity, and is thought to result in more ne
72                      Bisphosphonates inhibit osteoclast activity, and previous studies showed that th
73 an Igs, high blood calcium levels, increased osteoclast activity, and severe resorption of the human
74 truction, cartilage prostaglandin depletion, osteoclast activity, and Th17 production.
75 dihydroxyvitamin D(3), as well as markers of osteoclast activity, and the number of resorption lacuna
76                     Bisphosphonates suppress osteoclast activity, and their intravenous use has been
77 n in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the genera
78                          Blockade of ongoing osteoclast activity appears to have the potential to red
79 theless, osteoporosis drugs that target only osteoclast activity are expected to preserve bone format
80         Although the mechanisms of increased osteoclast activity are partially understood, comparativ
81 mercially available DFDBA samples on porcine osteoclast activity as measured by resorption on calcium
82 bone remodeling; they control osteoblast and osteoclast activities both directly via cell-to-cell com
83 eoprotegerin (OPG), bisphosphonates suppress osteoclast activity but not osteoclast numbers.
84 -CSF)-induced signaling, c-Src is central to osteoclast activity, but not differentiation.
85       We investigated how 14-3-3zeta affects osteoclast activity by evaluating its role in RANKL sign
86           We also showed that stimulation of osteoclast activity by parathyroid hormone is dependent
87 inflammatory arthritis, the dysregulation of osteoclast activity by proinflammatory cytokines, includ
88                                Activation of osteoclast activity by receptor activator of nuclear fac
89 at-like fashion to modulate murine and human osteoclast activity by transcriptionally repressing an A
90                           In these diseases, osteoclast activity causes bone loss that leads to pain,
91 other factors, they participate in increased osteoclast activity, decreased osteoblast function, and
92             Serum N-telopeptide, a marker of osteoclast activity, decreased significantly after zoled
93 he increases in Arf(-/-) ribosome output and osteoclast activity, demonstrating that these gains requ
94       Zoledronic acid, a potent inhibitor of osteoclast activity, differentiation, and survival, decr
95 mod(-/-) TMJs, including 5 genes involved in osteoclast activity/differentiation.
96 ve shared, non-redundant roles in regulating osteoclast activity during the formation of the adult sk
97 n bone obtained from patients with increased osteoclast activity exhibited increased NOX4 expression.
98                   Importantly, the values of osteoclast activity fall within those published previous
99 n tumor-bearing mice, OPG treatments reduced osteoclast activity from approximately 2-fold above norm
100 determinants of bone remodelling that affect osteoclast activity have been characterized, but the mol
101 ays that require c-Src expression for normal osteoclast activity have not been elucidated.
102           Cortical porosity is the result of osteoclast activity; however, the etiology of marrow fib
103 sely, alendronate treatment, which restricts osteoclast activity, improved bone quality but not aneur
104 s and bone mineral density without affecting osteoclast activities in young mice.
105 hondral bone-plate associated with increased osteoclast activity in both male and female bGH compared
106 fically inhibit bone resorption, the lack of osteoclast activity in c-fos-/- mice, and a new transgen
107 essfully monitored a significant increase in osteoclast activity in hindlimb long bones and its atten
108 sociated with the phagosome, genes linked to osteoclast activity in rheumatoid arthritis signaling, a
109 formation provides a rationale for increased osteoclast activity in the anabolic effects of PTH in ad
110 increased osteoblast activity and diminished osteoclast activity in the HMWKO.
111 ring GL64 prevented bone loss and suppressed osteoclast activity in the osteoporosis mouse model indu
112 last-activating factors but rather stimulate osteoclast activity in the presence of human bone marrow
113 udy, we report on the intravital tracking of osteoclast activity in three distinct murine bone diseas
114 se (TRAP)-positive cell number, and enhanced osteoclast activity in TMJ subchondral trabecular bone o
115 and Kp-10 abrogated bone loss by suppressing osteoclast activity in vivo.
116  deficiency in osteopetrosis and to modulate osteoclast activity in vivo.
117 ide of type I collagen, suggesting decreased osteoclast activity in vivo.
118 ed both basal and metabolic acidosis-induced osteoclast activity indicating osteoclast OGR1 is import
119          Here, we demonstrate that sustained osteoclast activity is largely due to accumulation of NO
120                                    Increased osteoclast activity is responsible for the enhanced bone
121 cal bone remodeling, but localized excessive osteoclast activity is responsible for the periarticular
122 olipase C gamma 2 (PLCG2) to cause excessive osteoclast activity leading to expansile lesions in faci
123 iodontal disease, and osteoporosis, elevated osteoclast activity leads to bone destruction.
124                                    Excessive osteoclast activity leads to bone loss and contributes t
125                                    Defective osteoclast activity leads to osteopetrosis and bone marr
126                 A balance of osteoblasts and osteoclasts activities maintains bone homeostasis.
127                   These results suggest that osteoclast activity may not be critical for the developm
128                                              Osteoclast activity, measured using a rat neonatal calva
129       Specifically, the model indicated that osteoclast activity must vary greatly (> 17-fold) to ret
130 clast function, either by directly promoting osteoclast activity or by inhibiting osteoclast signalin
131 zoledronic acid (Zol), a potent inhibitor of osteoclast activity/osteoclastogenesis and promoter of o
132 ator of nuclear factor-kappaB ligand-induced osteoclast activity over concentration ranges that repre
133 (P <0.05), alveolar bone loss (P <0.05), and osteoclast activity (P <0.05) throughout the experimenta
134 se results emphasize the important role that osteoclast activity plays in the establishment of CaP sk
135 bits multiple myeloma cell proliferation and osteoclast activity, potentially by controlling NF-kappa
136 tifying the molecular pathways that regulate osteoclast activity provides a key to understanding the
137 tifying the molecular pathways that regulate osteoclast activity provides a key to understanding the
138 sive crises (VOCs), increased bone turnover, osteoclast activity (RankL), and osteoclast recruitment
139 togenesis (Runx2, Sparc), and increased both osteoclast activity (RankL, Cathepsin k) and osteoclast
140 g that SMURF2 regulates osteoblast-dependent osteoclast activity rather than directly affecting the o
141 the mechanism that uncouples osteoblast from osteoclast activities remains unexplained.
142 ated to osteoblast impairment, and increased osteoclast activity resulted from local hypoxia, oxidati
143 n reduced bone formation, and an increase in osteoclast activity, resulting in increased bone resorpt
144 tyrosine phosphatase (PTP-oc), essential for osteoclast activity, shows sequence identity with the in
145 es was accompanied by increased staining for osteoclast activity, suggesting that there was a sex-spe
146 t lower LPS doses, other pathways leading to osteoclast activity that are independent of TNF and IL-1
147 ltiple myeloma is characterized by increased osteoclast activity that results in bone destruction and
148  and enhancing angiogenesis while modulating osteoclast activity to achieve net new bone formation, a
149 hypothesis that breast cancer cells modulate osteoclast activity using multiple regulatory factors th
150 f remodeling-based bone formation coupled to osteoclast activity versus modeling-based bone formation
151 (BMP2) and it has been implicated in reduced osteoclast activity via Guanine nucleotide-binding prote
152 tein 6 (TRIP6) in sealing zone formation and osteoclast activity was examined.
153      Accordingly, direct evidence of reduced osteoclast activity was found in transgenic mouse skulls
154   Finally, a significant increase of chondro-osteoclast activity was observed in the P3 MSC sheet-gra
155                                          The osteoclast activity was positively correlated with OARSI
156                   Over the course of a week, osteoclast activity was responsible for resorbing the ne
157     Epithelial downgrowth, inflammation, and osteoclast activity were evaluated; alveolar bone loss w
158 ed bone density although both osteoblast and osteoclast activity were increased.
159    Immunohistochemical staining of RANKL and osteoclast activity were significantly lower in the Mel-
160                      Bisphosphonates inhibit osteoclast activity, which is central to the development
161 eogenic markers, coupled with an increase in osteoclast activity, which resulted in a slight increase
162          Such bidirectional signaling limits osteoclast activity while stimulating osteoblast differe
163 er, there is a lack of studies investigating osteoclast activity within deep-seated bone lesions usin

 
Page Top